We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current KYMR market cap is 2.92B. The company's latest EPS is USD -3.4376 and P/E is -13.06.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 10.29M | 25.65M | 3.74M | 7.39M | 22.1M |
| Operating Income | -52.91M | -50.93M | -72.12M | -80.76M | -74.43M |
| Net Income | -48.56M | -42.06M | -62.49M | -70.75M | -65.58M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 34.03M | 72.83M | 46.83M | 78.59M | 47.07M |
| Operating Income | -46.3M | -100.53M | -161.26M | -165.53M | -256.71M |
| Net Income | -54.64M | -100.22M | -154.81M | -146.96M | -223.86M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 868.25M | 826.02M | 1.03B | 978.04M | 918.31M |
| Total Liabilities | 157.05M | 141.1M | 141.91M | 142.42M | 132.08M |
| Total Equity | 711.2M | 684.92M | 892.93M | 835.62M | 786.23M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 487.18M | 605.91M | 603.13M | 575.76M | 978.04M |
| Total Liabilities | 203.29M | 146.27M | 112.98M | 180.79M | 142.42M |
| Total Equity | 283.89M | 459.64M | 490.15M | 394.97M | 835.62M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -39.59M | -82.53M | -132.72M | -194.5M | -79.15M |
| Investing | -330.61M | -314.97M | -472.65M | -404.08M | 48.62M |
| Financing | 353.76M | 355.17M | 606.09M | 608.85M | 258k |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 88.13M | -128.95M | -153.09M | -102.83M | -194.5M |
| Investing | -422.59M | -99.84M | 20.52M | 139.89M | -404.08M |
| Financing | 289.26M | 250.28M | 153M | 4.19M | 608.85M |
| Market Cap | 2.92B |
| Price to Earnings Ratio | -13.06 |
| Price to Sales Ratio | 62.12 |
| Price to Cash Ratio | 24.32 |
| Price to Book Ratio | 3.5 |
| Dividend Yield | - |
| Shares Outstanding | 65.12M |
| Average Volume (1 week) | 681.61k |
| Average Volume (1 Month) | 906.28k |
| 52 Week Change | 5.90% |
| 52 Week High | 53.27 |
| 52 Week Low | 19.445 |
| Spread (Intraday) | 6.22 (12.39%) |
| Company Name | Kymera Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.kymeratx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
